Mankind Pharma Ltd. (IN:MANKIND)
:MANKIND
Want to see IN:MANKIND full AI Analyst Report?
MANKIND Stock Chart & Stats
₹2202.55
-₹40.15(-1.38%)
At close: 4:00 PM EST
₹2202.55
-₹40.15(-1.38%)
Day’s Range― - ―
52-Week Range₹1,909.90 - ₹2,726.75
Previous CloseN/A
Volume302.66K
Average Volume (3M)10.08K
Market Cap
₹935.47B
Enterprise Value₹1.01T
Total Cash (Recent Filing)₹31.05B
Total Debt (Recent Filing)₹83.69B
Price to Earnings (P/E)55.5
Beta0.49
Next Earnings
Jun 02, 2026EPS Estimate
10.15Next Dividend Ex-DateN/A
Dividend Yield0.04%
Share Statistics
EPS (TTM)12.10
Shares Outstanding412,828,340
10 Day Avg. Volume5,924
30 Day Avg. Volume10,081
Financial Highlights & Ratios
PEG Ratio16.80
Price to Book (P/B)6.94
Price to Sales (P/S)8.15
P/FCF Ratio50.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹2,800.00Price Target Upside27.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)57.57
Revenue Forecast (FY)₹159.53B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained high revenue growth indicates expanding product adoption and effective commercial execution in core therapy areas. Durable top-line expansion supports continued reinvestment into marketing, product launches and scale benefits that can compound margins and address multiple therapy segments over 2–6 months and beyond.
High ProfitabilityRobust gross and operating margins point to structural pricing power and efficient manufacturing/SG&A leverage in branded formulations. High profitability creates sustainable internal capital for R&D, market expansion and buffer against pricing pressure, supporting durable earnings quality and resilience.
Balance Sheet & Cash GenerationPrudent leverage and a strong equity base combined with positive free cash flow growth indicate financial flexibility to fund growth, M&A or capex without stressing liquidity. Reliable operating cash conversion enhances long-term solvency and reduces refinancing risk across economic cycles.
Bears Say
Earnings DeclineA material negative EPS print despite revenue growth signals margin pressure, one-offs, or rising costs that erode shareholder earnings. Persistent EPS weakness can reduce reinvestment capacity and investor confidence and may indicate underlying profitability volatility over the medium term.
Domestic Revenue ConcentrationHeavy reliance on the Indian branded formulations market concentrates regulatory, pricing and competitive risks. Domestic policy shifts, price controls or intensified generic competition could materially affect revenue and margins, limiting geographic diversification benefits in the medium term.
Limited Forward GuidanceAbsence of forward guidance reduces visibility into management's near-term plans and makes forecasting earnings and capital allocation harder for investors. Over 2–6 months, this can amplify uncertainty around targets, dampen accountability and impede market assessment of strategic execution.
Mankind Pharma Ltd. News
MANKIND FAQ
What was Mankind Pharma Ltd.’s price range in the past 12 months?
Mankind Pharma Ltd. lowest stock price was ₹1909.90 and its highest was ₹2726.75 in the past 12 months.
What is Mankind Pharma Ltd.’s market cap?
Mankind Pharma Ltd.’s market cap is ₹935.47B.
When is Mankind Pharma Ltd.’s upcoming earnings report date?
Mankind Pharma Ltd.’s upcoming earnings report date is Jun 02, 2026 which is in 34 days.
How were Mankind Pharma Ltd.’s earnings last quarter?
Mankind Pharma Ltd. released its earnings results on Feb 03, 2026. The company reported ₹12.1 earnings per share for the quarter, beating the consensus estimate of ₹12.038 by ₹0.062.
Is Mankind Pharma Ltd. overvalued?
According to Wall Street analysts Mankind Pharma Ltd.’s price is currently Undervalued.
Does Mankind Pharma Ltd. pay dividends?
Mankind Pharma Ltd. pays a Notavailable dividend of ₹1 which represents an annual dividend yield of 0.04%. See more information on Mankind Pharma Ltd. dividends here
What is Mankind Pharma Ltd.’s EPS estimate?
Mankind Pharma Ltd.’s EPS estimate is 10.15.
How many shares outstanding does Mankind Pharma Ltd. have?
Mankind Pharma Ltd. has 412,828,340 shares outstanding.
What happened to Mankind Pharma Ltd.’s price movement after its last earnings report?
Mankind Pharma Ltd. reported an EPS of ₹12.1 in its last earnings report, beating expectations of ₹12.038. Following the earnings report the stock price went up 4.296%.
Which hedge fund is a major shareholder of Mankind Pharma Ltd.?
Currently, no hedge funds are holding shares in IN:MANKIND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mankind Pharma Ltd.
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. Mankind Pharma Limited was founded in 1986 and is based in New Delhi, India.
MANKIND Stock 12 Month Forecast
Average Price Target
₹2,800.00
▲(27.13% Upside)
Technical Analysis
Alkem Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―
Torrent Pharmaceuticals Ltd
―
Zydus Lifesciences Limited
―